Cys80 Decapped Immunoglobulin Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The heterogeneity of monoclonal antibodies resulting from lysine or cysteine conjugation methods leads to variations in drug load and pharmacokinetic properties, complicating manufacturing and potentially affecting efficacy in therapeutic applications.
Innovation Solution
Decapping cysteine at position 80 in the light chain variable region of immunoglobulins and conjugating thiol-reactive compounds to achieve a more controlled and homogeneous conjugation, allowing for the generation of antigen-binding molecules with specific properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lysine-based conjugation is used to attach functional agents to antibodies, then the conjugation process is straightforward and efficient, but the final product becomes a heterogeneous mixture with varying drug-to-antibody ratios
Solution Approach 1:
The patent introduces a specifically engineered cysteine residue at a defined position (e.g., position 238 in the heavy chain or position 88 in the light chain) to serve as a localized conjugation site. This localized approach replaces the global lysine conjugation with a site-specific cysteine conjugation, ensuring that the functional agent attaches at a precise location on the antibody, thereby achieving homogeneous drug-to-antibody ratios while maintaining efficient conjugation
Solution Approach 2:
The patent changes the chemical parameter of the conjugation site from lysine (amine group) to cysteine (thiol group), and further modifies the oxidation state by controlling disulfide bond formation. This parameter change enables controlled conjugation stoichiometry and homogeneous DAR ratios, as the thiol-reactive chemistry provides more predictable and uniform attachment compared to amine-based conjugation
2Manufacturing precision
If cysteine-based conjugation is used to attach functional agents to antibodies, then site-specific conjugation is achieved, but partial reduction of disulfide bonds is required which complicates the process and creates heterogeneity
Solution Approach 1:
The patent performs preliminary engineering of the antibody sequence to include a specifically designed cysteine residue at a predetermined location that is naturally accessible and does not participate in native disulfide bonds. This preliminary action eliminates the need for partial reduction steps during conjugation, as the engineered cysteine is already in a reduced, free-thiol state ready for immediate conjugation with thiol-reactive compounds
Solution Approach 2:
The patent introduces an engineered cysteine residue as an intermediary conjugation site that mediates between the antibody structure and the functional agent. This intermediary cysteine is strategically positioned to be accessible for conjugation while maintaining structural integrity, serving as a dedicated docking site that simplifies the conjugation process by eliminating the need for disulfide bond reduction
3Manufacturing precision
If multiple cysteines are conjugated to achieve homogeneous drug load, then drug-to-antibody ratio uniformity is improved, but the number of possible conjugation species increases leading to manufacturing challenges
Solution Approach 1:
The patent introduces specifically engineered cysteine residues at predetermined positions on the antibody heavy and/or light chains to serve as localized conjugation sites. By controlling the number and position of these engineered cysteines, the patent achieves homogeneous drug-to-antibody ratios while limiting the number of possible conjugation species, thereby simplifying manufacturing compared to unconstrained multi-cysteine conjugation
Solution Approach 2:
The patent modifies the antibody sequence to include a defined number of engineered cysteine residues with specific properties (e.g., accessibility, pKa, proximity to each other). This parameter change in the molecular structure allows for controlled and predictable conjugation stoichiometry, achieving homogeneous DAR ratios while minimizing the complexity of the resulting conjugate mixture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of conjugated immunoglobulins with consistent drug load and improved stability, enhancing their therapeutic efficacy and manufacturing efficiency.
Implementation Method 1
conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3
AI summary
Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 ("Cys80") in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.